Premium
Anti‐arthritic effects demonstrated by an interleukin‐2 receptor‐targeted cytotoxin (DAB 486 IL‐2) in rat adjuvant arthritis
Author(s) -
Bacha Patricia,
Forte Serene E.,
Perper Stuart J.,
Trentham David E.,
Nichols Jean C.
Publication year - 1992
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.1830220702
Subject(s) - rheumatoid arthritis , immunology , arthritis , interleukin 2 , receptor , adjuvant , interleukin , inflammation , antibody , interleukin 6 receptor , biology , pharmacology , interleukin 6 , medicine , cytokine
Abstract DAB 486 IL‐2 is an interleukin‐2 receptor‐specific cytotoxin which selectively targets and kills cells which bear the high‐affinity form of the IL‐2 receptor. Since elimination of activated T lymphocytes may be useful in the treatment of rheumatoid arthritis, the effect of DAB 486 IL‐2 treatment in an animal model of arthritis was investigated. We demonstrated that rats treated with DAB 486 IL‐2 during the induction phase of disease have delayed onset of symptoms and significantly reduced severity of inflammation as well as a depressed proliferative response to mycobacterial stimulation in vitro. In addition, the presence of preexisting antibodies to the molecule had no impact on the anti‐arthritic effects observed in this model. These data suggest that DAB 486 IL‐2 may have therapeutic potential in the treatment of rheumatoid arthritis.